545 related articles for article (PubMed ID: 19196199)
1. Bluetongue vaccines: the past, present and future.
Bhanuprakash V; Indrani BK; Hosamani M; Balamurugan V; Singh RK
Expert Rev Vaccines; 2009 Feb; 8(2):191-204. PubMed ID: 19196199
[TBL] [Abstract][Full Text] [Related]
2. Vaccines against bluetongue in Europe.
Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
[TBL] [Abstract][Full Text] [Related]
3. Vaccines for Prevention of Bluetongue and Epizootic Hemorrhagic Disease in Livestock: A North American Perspective.
McVey DS; MacLachlan NJ
Vector Borne Zoonotic Dis; 2015 Jun; 15(6):385-96. PubMed ID: 26086559
[TBL] [Abstract][Full Text] [Related]
4. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus.
Barros SC; Cruz B; Luís TM; Ramos F; Fagulha T; Duarte M; Henriques M; Fevereiro M
Vet Microbiol; 2009 Jun; 137(3-4):252-9. PubMed ID: 19233575
[TBL] [Abstract][Full Text] [Related]
5. Cell-mediated immune response and cross-protective efficacy of binary ethylenimine-inactivated bluetongue virus serotype-1 vaccine in sheep.
Umeshappa CS; Singh KP; Pandey AB; Singh RP; Nanjundappa RH
Vaccine; 2010 Mar; 28(13):2522-31. PubMed ID: 20117268
[TBL] [Abstract][Full Text] [Related]
6. Current and next-generation bluetongue vaccines: Requirements, strategies, and prospects for different field situations.
Feenstra F; van Rijn PA
Crit Rev Microbiol; 2017 Mar; 43(2):142-155. PubMed ID: 27800699
[TBL] [Abstract][Full Text] [Related]
7. Bluetongue virus: virology, pathogenesis and immunity.
Schwartz-Cornil I; Mertens PP; Contreras V; Hemati B; Pascale F; Bréard E; Mellor PS; MacLachlan NJ; Zientara S
Vet Res; 2008; 39(5):46. PubMed ID: 18495078
[TBL] [Abstract][Full Text] [Related]
8. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
[TBL] [Abstract][Full Text] [Related]
9. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
[TBL] [Abstract][Full Text] [Related]
10. Vaccination in the control of bluetongue in endemic regions: the South African experience.
Dungu B; Potgieter C; Von Teichman B; Smit T
Dev Biol (Basel); 2004; 119():463-72. PubMed ID: 15742661
[TBL] [Abstract][Full Text] [Related]
11. Recombinant vaccines against bluetongue virus.
Calvo-Pinilla E; Castillo-Olivares J; Jabbar T; Ortego J; de la Poza F; Marín-López A
Virus Res; 2014 Mar; 182():78-86. PubMed ID: 24287057
[TBL] [Abstract][Full Text] [Related]
12. Bluetongue vaccines.
Noad R; Roy P
Vaccine; 2009 Nov; 27 Suppl 4():D86-9. PubMed ID: 19837295
[TBL] [Abstract][Full Text] [Related]
13. Potency and efficacy of inactivated bluetongue virus vaccines.
Stevens DR; Stott J; Osburn BI; Giles R; Wiesehahn GP; Barber TL
Prog Clin Biol Res; 1985; 178():649-52. PubMed ID: 2989914
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of three inactivated vaccines against bluetongue virus serotype 8 in sheep.
Eschbaumer M; Hoffmann B; König P; Teifke JP; Gethmann JM; Conraths FJ; Probst C; Mettenleiter TC; Beer M
Vaccine; 2009 Jun; 27(31):4169-75. PubMed ID: 19406189
[TBL] [Abstract][Full Text] [Related]
15. Protective duration of immunity of an inactivated bluetongue (BTV) serotype 2 vaccine against a virulent BTV serotype 2 challenge in sheep.
Hamers C; Rehbein S; Hudelet P; Blanchet M; Lapostolle B; Cariou C; Duboeuf M; Goutebroze S
Vaccine; 2009 May; 27(21):2789-93. PubMed ID: 19366576
[TBL] [Abstract][Full Text] [Related]
16. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge.
Wade-Evans AM; Romero CH; Mellor P; Takamatsu H; Anderson J; Thevasagayam J; Fleming MJ; Mertens PP; Black DN
Virology; 1996 Jun; 220(1):227-31. PubMed ID: 8659119
[TBL] [Abstract][Full Text] [Related]
17. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
[TBL] [Abstract][Full Text] [Related]
18. Assessment of efficacy of a bivalent BTV-2 and BTV-4 inactivated vaccine by vaccination and challenge in cattle.
Savini G; Hamers C; Conte A; Migliaccio P; Bonfini B; Teodori L; Di Ventura M; Hudelet P; Schumacher C; Caporale V
Vet Microbiol; 2009 Jan; 133(1-2):1-8. PubMed ID: 18617335
[TBL] [Abstract][Full Text] [Related]
19. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep.
Boone JD; Balasuriya UB; Karaca K; Audonnet JC; Yao J; He L; Nordgren R; Monaco F; Savini G; Gardner IA; Maclachlan NJ
Vaccine; 2007 Jan; 25(4):672-8. PubMed ID: 17059856
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
